TUBB2B and prostate carcinoma: It was prioritized for validation as a TUBB2B-binding partner, because of its critical function in cell proliferation and apoptosis [21] as well as its implications in a variety of cancers, including HCC, B cell lymphoma, colorectal cancer, prostate cancer and breast cancer [22–26].